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Abstract
Human papillomavirus (HPV) accounts for approximately 4.5% of all cancers 
which differs at the level of economic development and geographical regions. The 
life cycle of the HPV is completely dependent on the epithelium differentiation 
without the involvement of cell death and systemic viremia. Carcinogenesis is the 
consequence of viral gene expression, dysregulated cell proliferation, and genomic 
instability. Keratinocytes are the target cell for HPV which act as the physical and 
immunological barrier. In cervical carcinogenesis, the enhanced level of Th17 
infiltration has been observed which increases with the disease progression and is 
coupled with CCL20 expression in the stromal mesenchymal compartment. IL-6 
and M-CSF are known as “switch factors” which are imperative for pro-tumorigenic 
response in monocytes. Screening of cervical cancer includes three major pro-
cedures: cytology, nucleic acid test, and co-testing. For evaluating anal lesions, 
high-resolution anoscopy is performed which is similar to colposcopy. Prophylactic 
vaccination is the primary preventive measure to control the HrHPV infection and 
reduce the burden of HPV-related cancer. The precancerous stage of HPV infec-
tion includes excision, ablation, and immunotherapy. Radiotherapy is the accept-
able primary treatment for the early stage of anogenital cancer, whereas for the 
advanced-stage metastatic cancer, palliative therapy is the only option.
Keywords: HPV, infection, management, prevention
1. Introduction
Human papillomavirus (HPV) attributes to approximately 4.5% of all 
cancers which differs at the level of economic development and geographical 
regions [1]. Papillomaviridae family comprises of more than 200 types of HPV 
which are classified into five genera: Alphapapillomavirus, Betapapillomavirus, 
Gammapapillomavirus, Mupapillomavirus, and Nupapillomavirus [2]. All the genera 
are responsible for the various types of HPV-associated cancers. Furthermore, on the 
basis of oncogenicity, the mucosal type (alpha) is grouped into two subtypes which 
are low risk (LR), HPV 6 and HPV 11, which are known to cause benign genital warts 
and high-risk (HR) cervical cancer [3]. HPV 6 and HPV 11 are also known to cause 
respiratory papillomatosis predominantly in children [4]. According to IARC clas-
sification, high-risk HPV (HrHPV) is of 14 types: HPV 16, HPV 18, HPV 31, HPV 33, 
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HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and 
HPV 68 [5]. High-risk papillomavirus is responsible for causing cancer related to the 
cervix, vulva, vagina, anus, penis, and oropharynx [6]. HPV 16 and HPV 18 repre-
sent approximately 60% for adenocarcinoma of the endocervix (ADC-CX), and both 
are equally associated with 15% of adenosquamous carcinoma (ASC) of the endocer-
vix [7]. Among the HrHPV, HPV 16 is the most efficient in evading the host immune 
response and responsible for persistent infection in the oropharynx, an imperative 
step in development of malignant lesion [8]. The mucosal HPV is transmitted by 
sexual contacts, and the transformation zone in females is characterized as the area 
adjacent to the border of the ecto- and endocervix which are the preferential sites of 
primary infection [9]. Approximately 80% of the sexually active women get HPV 
infection where most of them are asymptomatic with the immune system-mediated 
clearance of infection within 6–12 months [10]. With the impairment of immune 
function, the infection becomes symptomatic in a small number of individuals. 
Persistent infection of HPV and the development of cervical intraepithelial neoplasia 
(CIN) after the period of latency may lead to the regression or progression toward 
the development of invasive carcinoma [11]. The prevalence of HPV infection is 
higher in immunocompromised individuals such as HIV [12] and organ transplant 
recipients (OTRs) [13] suggesting the role of T cell in the clearance of HPV. Other 
factors including smoking, parity, sexual habits, genetic factors, oral-contraceptives 
have shown to increase the risk of progression of HPV-driven diseases [14].
Beta genus of HPV principally accounts for progression of nonmelanoma 
skin cancer (NMSC). The association of beta HPV types with skin cancer can be 
explained as the prevalence of epidermodysplasia verruciformis (EV). Patients 
diagnosed with EV are highly susceptible for HPV beta-type infection which results 
in flat warts and pityriasis versicolor-like lesions [15]. With the advancement detec-
tion methods, beta HPV types have been shown to be abundantly present in the skin 
of the asymptomatic HPV-infected individuals. So far, 43 HPV of beta genus have 
been isolated. Furthermore, beta HPV types have been speculated as HPV facilitates 
the accumulation of ultraviolet-mediated DNA damage [16]. In order to prevent 
the disease, the neutralizing antibody (nAb) has been shown to provide protection. 
However, immunization with attenuated or killed pathogen is imperative.
2. Global HPV epidemiology
The global burden of HPV-driven cervical cancer accounts for approximately 
630,000 cases annually [1] where five other HPV-associated sites of cancer are 
responsible for further 113,400 cases [17]. In spite of the availability of several 
preventive strategies, HPV subtypes cause worldwide morbidity and mortality 
particularly in the less developed countries (Figure 1) [18]. Asia contributes to the 
immense majority of cervical cancer cases of 285,000 with 144,000 deaths fol-
lowed by Africa where 99,000 cases with 60,000 deaths and America with 83,000 
newer cases with 36,000 deaths. Asia, China, and India contribute to 62,000 and 
123,000 cases along with 30,000 and 67,000 deaths, respectively [19]. Data from 
the meta-analysis and systemic reviews are suggesting that the vast majority of the 
infection is asymptomatic and transient. The incidence of HPV infection particu-
larly cervical cancer is higher in sub-Saharan Africa (SSA) [20]. The worldwide 
distribution of age-specific HPV infection also varies with the predominance in 
young women of age less than 25 years in Europe and America [21]. However, 
in Africa and Asia no significant decline with the age has been observed. 3.2% 
of HPV 16 infected women shows normal cytology [22]. Cervical precancerous 
lesion is an imperative factor for HPV prevalence where HPV is detected in 52.5% 
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of ascus lesion, 74.8% of low-grade cervical lesions, and 88.9% of high-grade 
cervical lesions. HPV 16 has been detected in 19.3% of low- and 45.1% of high-
grade cervical lesions [23]. Furthermore, anal HPV infection is the most frequent 
HPV infection of other anogenital areas. The global burden of anogenital cancers 
caused by HPV is very high where 88% of anal and <50% of cases attribute to the 
lower genital tract [24]. About 30,000 cases are reported in men with the 56.56% 
attributed to the anus and 43.33% to penile origin. In the case of women, 38,500 
cases are reported with 46.75% cases attributed to the anus, 22% to the vulva, and 
31.16% from the vaginal origin [1]. Furthermore, the predominance of anal HPV 
infection that has been observed in the men sex with men (MSM) is 58.8% or HIV-
infected individuals. The oral HPV infection significantly differs by gender and 
with higher incidence in men [19]. The worldwide prevalence of HPV-associated 
head and neck cancer is 8.15%, that is, 37,200 cases, where 77.95% of cases belong 
to the oropharynx, 11.82% of cases correspond to the oral cavity, and 10.21% of 
cases correspond to the larynx [1].
3. HPV genome and replication
Human papillomavirus is a histone-bound double-stranded DNA virus of ~8 kb 
with either eight or nine open reading frames (ORFs) on the same DNA strand. 
HPV genome can be subdivided into three regions: coding region comprises of early 
genes such as E1, E2, E4, E5, E6, and E7; region encoding major (L1) and minor 
(L2) capsid proteins; and a noncoding region present between ORFs L1 and E6 
known as long control region (LCR), involving in viral DNA replication and tran-
scriptional regulation [25]. HPV genome is highly conserved; however, exclusive 
features are represented by different genera. As compared with the mucosal HPV 
types, beta HPV genome is relatively shorter due to reduced size of LCR (400 bp) 
which ranges from 7.4–7.7 kb, whereas the E2 ORF is relatively larger in beta HPV 
types (Figure 2) [26]. Apart from this, most of the beta HPV types lack E5 gene 
with the exception of HPV 14 [27]. An additional early protein, E8Ê2C, is expressed 
exclusively by some of the HrHPV types as HPV 16, HPV 18, and HPV 31 that 
repress the expression of viral oncoproteins E6 and E7 following proliferation [28]. 
Figure 1. 
Worldwide prevalence of HPV (n = 1938) [adapted from ref. 18].
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Recently, three gamma HPV types (101, 103, and 108) have been isolated from the 
cervical specimens which lack the E6 ORF [29].
Epithelial abrasion is the typical site of HPV infection where the squamocolum-
nar junction (SCJ) of the cervix is susceptible to HPV transformation [9]. The life 
cycle of the HPV is completely dependent on the epithelium differentiation without 
the involvement of cell death and systemic viremia. Heparan sulfate proteoglycans 
(HPSGs) are exposed by the epithelial abrasion which is the binding site for L1 
and defined as the extracellular event of HPV replication [30]. Upon binding the 
conformational changes in the capsid expose the N terminus of L2 which gets 
cleaved by extracellular furin, a prerequisite for the virus internalization [31]. Virus 
uptake is mediated by L1 and endosomal vesicles, following transport of endosomal 
virus to the nucleus along with the retromer. L1 is degraded, whereas L2 forms the 
complex with viral genome following the escape from endosome to the trans-Golgi 
networks [32]. L2 entry into the nucleus is dependent on the cell cycle progression 
and transpired upon transient nuclear membrane breakdown [33]. The L2 genome 
complex interacts with ND-10, a promyelocytic leukemia nuclear bodies follow-
ing initiation of early viral transcripts [34]. The host DNA replication machinery 
system is utilized by the viral early proteins E1 and E2 to establish 50–100 episomal 
copies per cells [35]. Dependence on host DNA replication system is the reason 
for the slow rate of virus evolution due to proofreading mechanism. The produc-
tive phase of HPV life cycle exhibits a unique spatial and temporal regulation and 
differentiation of keratinocyte in squamous epithelium. Upon leaving the basal 
membrane, HPV enters into the productive phase of life cycle which can be char-
acterized as high copy number (1000 copies per cell) of HPV genome along with 
Figure 2. 
HPV genome.
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the late viral capsid expression for assembly transpired only in the upper terminally 
differentiated epithelial layer (Figure 3) [36].
Several of the host factors also play an imperative role in HPV replication where 
HPV drives the keratinocytes into S phase of the cell cycle mediated by E5, E6, and 
E7 viral oncoproteins [37]. E5 increases the expression of epidermal growth factor 
receptor (EGFR) which promotes the progression toward G1 phase [38]. E6 medi-
ates proteasomal degradation upon binding with p53, a PDZ protein to promote 
de-differentiation of cells and other pro-apoptotic factors to promote the cell survival 
[39]. Moreover, MYC expression and telomerase get activated by E6 protein [40]. E7 
protein is known to bind with multiple targets specifically RB to overcome the restric-
tion points [41]. Primary keratinocytes get immortalized due to ectopic expression 
of E6 and E7 which also induces the genomic instability [42]. Carcinogenesis is the 
consequence of viral gene expression, dysregulated cell proliferation, and genomic 
instability; however, the progression of cancer is not beneficial to the virus.
4. Immunopathogenesis during HPV infection
The skin and mucosal surfaces act as the first line of defense during infection; 
however, cutaneous and mucosal HPV are known to diminish the recognition process 
mediated by TLR9 [43]. Mucosal HPV is known to inhibit the IFN signaling and 
expression which is mediated by both E6 and E7. HPV E6 protein interacts with IFN 
regulatory factor 3 (IRF3) [44], whereas E7 interferes with pro-apoptotic factor IRF1 
and antiviral [45]. Keratinocytes are the target cell for HPV which act as the physical 
and immunological barrier. The activation of inflammasome in keratinocytes by 
other DNA viruses results in acute inflammatory responses; however, diminished 
inflammatory response has been observed in mucosal HPV infection. Mucosal HPV 
oncoproteins are responsible for abrogated posttranslational modification and secre-
tion of IL-1β via targeting p300/CBP-associated factors/NF-κB pathway [46]. Upon 
infection the epithelial cells release chemotactic factors for recruiting, differentiation, 
and activation of Langerhans cells which are the professional antigen-presenting 
cells (APCs). HPV infection interferes with homeostasis of Langerhans cells in the 
Figure 3. 
HPV life cycle.
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epidermal compartment. Low levels of chemokines (CCL20 and CCL2) are mediated 
by HPV oncoproteins which result in the reduced level of APC recruitment toward 
the epithelium [47]. HPV infection during the progression of an invasive form of 
cancer results in expansion of epithelial stem cell compartments.
The increased level of stromal infiltration with the immune cells is associated 
with the increasing dysplasia. Secretion of chemoattractants is upregulated by HPV-
transformed cells, specifically the CCL2 production by monocytes which attracts 
myelomonocytic cells following maintenance of inflammatory microenvironment via 
CCR-2 dependent pathway. Remarkably, CCL-2 secretion results in higher produc-
tion of MMP-9 via intracellular Ca2+ signaling by monocytes [48]. MMP-9 has been 
shown to be involved in the progression toward malignancy where monocytes become 
infiltrating into high-grade cervical lesions. In cervical carcinogenesis, the enhanced 
level of Th17 infiltration has been observed which increases with the disease progres-
sion and is coupled with CCL20 expression in the stromal mesenchymal compart-
ment [49]. Most importantly, IL-6 and monocyte colony-stimulating factors (M-CSF) 
are known as “switch factors” which are imperative for pro-tumorigenic response in 
monocytes and are highly upregulated during the late stage of human cervical cancer 
which results in activation of JAK/STAT3 signaling pathway in monocytes [46]. In 
cervical cancer, inhibition of NF-κB in CD83+ dendritic cells is the consequence of 
the diminished CCR7 expression that leads to interrupted dendritic cell migration to 
the lymph node-homing chemokine. Antigen transport to the secondary lymphoid 
tissue by stromal dendritic cells gets impaired due to diminished CCR7 expression. 
Cervical cancer cell-derived IL-6 immobilizes the dendritic cells in the tumor stroma 
via suppression of CCR7 resulting in local MMP-9 production [50]. Furthermore, 
the low level of IFN-γ production by M2-polarized macrophages causes a reduced 
level of T-cell proliferation in cervical cancer stroma [51]. The programmed cell death 
ligand-1 (PD-1) is expressed by most of the CD8+ T cells in cervical cancer, and the 
suppressed cytotoxic cell response is probably due to M2-macrophages [52].
5. Diagnosis for HPV
Screening of cervical cancer includes three major procedures: cytology (micro-
scopic evaluations of sample acquired from cervical regions), nucleic acid test 
(detection of HrHPV DNA or RNA), and co-testing (combination of microscopy 
and nucleic acid test) [53]. In the clinical settings, some of the routine tests for 
HPV detection are biopsy, DNA-based test, Pap smear, colposcopy, and acetic acid 
test. Colposcopy is the clinical examination of the cervix, vagina, and vulva upon 
application of acetic acid solution which is known as visual inspection with acetic 
acid (VIA) and is mostly coupled with biopsy of regions suspected of neoplasia 
[54]. Colposcopy findings are evaluated and represented on the basis of acetowhite 
lesion, mosaic pattern, punctuation, and surface contour [55]. Due to the higher 
chance of false-positive results, colposcopy screening is recommended for various 
conditions such as HIV-infected individuals, dyskaryosis, borderline nuclear change 
in endocervical cells, and cervical cytology positive for malignant [56].
For evaluating anal lesions, high-resolution anoscopy is performed which is 
similar to colposcopy. However, anoscopy is more complex since it requires manipula-
tion to visualize the entire SCJ along with lower accuracy. High-resolution anoscopy 
is performed as a first-line test for HPV surveillance in MSM population to follow up 
anal cytological findings [57]. Histopathological evaluations are considered as the 
reference standards for deciding the treatment in precancerous or cancerous stages 
of HPV [58]. CIN3 is considered as the precancerous stage of the HPV infection and 
can be treated, whereas CIN1 is the morphological representation of HPV infection 
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and cannot be treated [59]. The CIN2 lesions are considered as severe appearing 
HPV infection rather than a precancerous one. Several of the biomarkers have been 
developed to screen CIN2 form of HPV infection. p16 staining can be used to dis-
criminate among the p16-positive CIN2 with CIN3 and p16-negative with CIN1 [60]. 
DNA-based test utilizes the principle of direct probe hybridization such as dot blot 
and Southern blot which are associated with disadvantages as low sensitivity and 
requirement of large amount of DNA sample. Currently, hybrid capture HPV DNA 
test 2 (HC2) and PCR-based test have been approved by the FDA [61]. HC2 test can 
be used to detect as low as 1 pg. of HPV DNA/ml and its sensitivity is comparable with 
PCR. HC2 can detect both low-risk (6, 11, 42, 43, 44) and high-risk (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 68) HPV. PCR-based diagnosis of HPV is more accurate and 
robust as compared to the Pap smear test which is a screening test for HPV detection.
6. Prevention and treatment
Prophylactic vaccination is the primary preventive measure to control the 
HrHPV infection and reduce the burden of HPV-related cancer [62]. Currently 
available vaccine for HPV comprises viruslike particles (VLPs) which is the major 
HPV coat protein L1. VLPs are noninfectious in nature which lacks DNA and have 
similar geometry to the native virus [63]. Currently, three prophylactic VLP vac-
cines have been licensed, namely, as the bivalent Cervarix, the nonavalent Gardasil, 
and the quadrivalent Gardasil [64]. Cervarix is based on the HPV 16 and HPV 
18 antigens and proprietary adjuvants for enhancement of immunogenicity [65]. 
While Gardasil provides protection against wide range of HPV such as HPV 6, HPV 
11, HPV 18, HPV 31, HPV 33, HPV 45, HPV 52, and HPV 52 [66]. All the vaccines 
are intended to provide complete protection against HPV if administered before the 
exposure and have been shown to be highly efficacious without any adverse effects. 
More than 64 countries have introduced the HPV vaccination program primarily 
targeting girls of age 9–13 and boys of higher age group [67]. In both males and 
females, systemic immunization with HPV vaccine results in higher amount of 
antibody generation as 1–1000 times higher than the natural infection.
The management of HPV infection depends on the type and severity of the HPV 
infection. For the precancerous stage of HPV infection, it includes treatment strate-
gies as excision, ablation, and immunotherapy. The gold standard for the manage-
ment of HPV treatment is various excisional procedures of the transformation zone 
where the extent of excision depends on the lesion size [68]. Ablation procedures 
are less invasive and include cold coagulation, laser therapy, and cryotherapy with 
the disadvantage of procurement of tissue sample for confirmatory diagnosis. The 
immunotherapy has shown to be effective but is still present in the clinical trial 
stages [69]. Anogenital cancers are treated by radical local excision and by regional 
lymphadenectomy during the spread of infection to the lymphatic system [70]. 
During cervical cancer radical hysterectomy which is the removal of the whole 
uterus including the upper vagina and supporting ligaments along with excision 
of paracervical soft tissue is performed. Surgical intervention not only defines the 
involvement of lymph nodes but also suggests the treatment alternatives as radio-
therapy and chemoradiotherapy.
Radiotherapy is the acceptable primary treatment for the early stage of 
anogenital cancer, whereas for the advanced-stage metastatic cancer, pal-
liative therapy is the only option. In the recurrent cervical cancer, the anti-
angiogenic treatment such as bevacizumab along with cisplatin and paclitaxel 
can prolong the survival [71]. In case of invasive form of cervical cancer, 
treatment is based on surgery, brachytherapy, external beam radiation, and 
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cisplatin-based chemotherapy [72]. In case of oropharyngeal squamous cell 
cancer, cisplatin-based chemotherapy has been the primary therapeutic approach 
[73]. Radiotherapy or surgical intervention is the choice of treatment during the 
primary early stage of oropharyngeal cancer.
7. Conclusions
Globally, over 4.6% of all the cancer cases are attributed to HPV each year where 
vast majority of the cases are of cervical cancer. HPV 16 and HPV 18 are predomi-
nantly responsible for progression toward cancer development. The greatest burden 
of HPV infection comes in the form of cervical cancer and can be prevented. 
The burden of cervical cancer in the form of high toll number can be reduced via 
vaccination, screening programs, and implementation of the early treatment along 
with palliation. Vaccination is the ultimate preventive strategy for all the forms of 
HPV-associated cancers, and the evidences are suggesting the safety of the strategy.
8. Future perspectives
From the last 36 years, the research in the area of HPV focuses on the prevention 
strategies and led to the development of vaccine and screening programs. However, 
new treatment for HPV infection and HPV-related cancer is still under investiga-
tion. Immunotherapy for the systemic treatment of HPV infection is the most 
promising area research worldwide, but none of them have been FDA approved. 
In order to reduce the burden of HPV-associated cancer, global implementation 
of vaccination and risk-based screening programs must be followed. The use of 
HPV-FASTER should be compelled to exemplify the current need of vaccination 
and screening among the higher prevalence of HPV in young generation. Currently, 
preventive vaccines are being developed targeting a wide range of HPV subtypes 
which might reduce and eventually eliminate the need of cervical cancer screening.
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